Schering-Plough

Schering-Plough
Name	Schering-Plough
Type	Public
Industry	Pharmaceuticals
Fate	Merged
Founded	1851
Founder	Ernst Christian Friedrich Schering
Defunct	2009
Headquarters	Kenilworth, New Jersey
Key people	Fred Hassan, Fred R. Hassan
Products	Pharmaceuticals, vaccines, consumer health
Num employees	23,600 (2009)

Schering-Plough was an American pharmaceutical company that operated from the 19th century until its 2009 merger. It developed prescription medicines, vaccines, and consumer health products and maintained global operations with research facilities and manufacturing sites. The company was active in cardiovascular, dermatology, and respiratory therapeutics and engaged in strategic transactions with multinational firms.

History

Schering-Plough traces corporate antecedents to chemist Ernst Christian Friedrich Schering and early European chemical enterprises; its U.S. lineage involved expansions in the 20th century with ties to firms such as Plough, Inc. and international connections to Schering AG. Corporate milestones included listings on the New York Stock Exchange and operations during periods shaped by regulatory frameworks like the Food and Drug Administration oversight. Leadership transitions involved executives who had prior roles at companies including Merck & Co. and Pfizer. The company navigated industry-wide shifts exemplified by consolidation waves similar to those involving GlaxoSmithKline and AstraZeneca.

Products and Research

Schering-Plough developed and marketed products spanning prescription drugs, vaccines, and consumer health brands. Notable therapeutic areas included dermatology products competing with offerings from Johnson & Johnson and Galderma, respiratory agents in classes alongside compounds by Boehringer Ingelheim and Novartis, and cardiovascular treatments in a market involving Bristol-Myers Squibb and AstraZeneca. Research collaborations and licensing agreements involved institutions such as National Institutes of Health and biotech firms like Genentech and Amgen. The company conducted clinical trials registered with regulators and engaged in biologics manufacturing technologies akin to platforms used by Sanofi and Roche.

Corporate Structure and Leadership

Corporate governance comprised a board of directors and executive officers with cross-industry experience from firms like Eli Lilly and Company and AbbVie. CEOs and chairpersons included executives who had served in leadership at firms such as Wyeth and GlaxoSmithKline. Schering-Plough maintained regional headquarters and research centers in locations comparable to those of Pfizer and Merck & Co., and its organizational structure reflected divisions for pharmaceuticals, vaccines, and consumer healthcare similar to structures at Procter & Gamble for consumer brands. Institutional investors included asset managers comparable to Vanguard Group and BlackRock that commonly hold stakes in major corporations.

Mergers and Acquisitions

The company was involved in strategic M&A, acquiring and divesting assets in sectors where firms such as Bayer and Novartis were active. The most consequential transaction was the 2009 combination with Merck & Co. in a deal that resulted in corporate integration and consolidation of research pipelines, mirroring consolidation trends seen in mergers like Wyeth with Pfizer. Prior acquisitions and licensing deals included collaborations with biotech companies resembling transactions with Vertex Pharmaceuticals and Genzyme. Antitrust review and shareholder votes for large transactions invoked regulatory scrutiny by agencies such as the Federal Trade Commission.

Legal and Regulatory Issues

Schering-Plough encountered regulatory and legal matters involving product approvals, labeling, and compliance similar to issues addressed by the Food and Drug Administration and judicial proceedings in federal courts such as the United States District Court for the District of New Jersey. The company managed patent litigation in forums comparable to cases before the United States Court of Appeals for the Federal Circuit and negotiated settlements resembling those involving GlaxoSmithKline and Pfizer in disputes over generic entry. Compliance programs were updated in response to enforcement actions by agencies analogous to the Department of Justice and investigations resembling inquiries into marketing practices conducted at other large pharmaceutical firms.

Philanthropy and Corporate Social Responsibility

Philanthropic initiatives included donations to healthcare institutions and partnerships with organizations such as American Red Cross, United Way, and global health programs linked to World Health Organization initiatives. Corporate social responsibility efforts focused on access to medicines and community health programs reminiscent of campaigns run by Bill & Melinda Gates Foundation partners and corporate foundations associated with Johnson & Johnson. Environmental and workplace practices followed industry standards promoted by bodies like the Environmental Protection Agency and labor frameworks similar to those advocated by International Labour Organization.

Category:Pharmaceutical companies of the United States Category:Companies formerly listed on the New York Stock Exchange